Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa
ConclusionsBased on the adapted model, docetaxel and paclitaxel are predicted to be cost-effective as adjuvant treatment for early breast cancer in South Africa.
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research
More News: African Health | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Docetaxel | International Medicine & Public Health | South Africa Health | Study | Taxotere | UK Health